WASHINGTON — Pharmaceutical and health insurance industry representatives on Wednesday sparred over the potential impacts of legislation to lower drug prices, underscoring an emerging flashpoint here as Congress attempts to broker sweeping pharmaceutical industry reforms.
The debate centered on a recent analysis showing Democrats’ signature drug pricing legislation would reduce the number of new drugs approved in the U.S. by eight to 15 in the coming decade. Yet Matt Eyles, the CEO of the insurance lobbying group America’s Health Insurance Plans, disagreed with the projection.
About the Author Reprints
